News Nicox glaucoma drug works, but not as well as hoped Nicox has had both good and bad news from a much-anticipated phase 3 trial of its glaucoma therapy candidate NCX 470.
R&D LSX 2024 - James Graham, Recce Pharma A lot of ink has been spilled about the anti-microbial resistance space and why it’s so hard to create a profitable company in it.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.